Cargando…
Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review
Diet therapy is an option for managing patients with drug-resistant epilepsy (DRE). Diet therapies used for patients with epilepsy include the classic ketogenic diet, the modified Atkins diet, the medium chain triglyceride diet, and the low glycemic index diet. The effectiveness of diet therapy is h...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574123/ https://www.ncbi.nlm.nih.gov/pubmed/34778739 http://dx.doi.org/10.1016/j.ebr.2021.100498 |
_version_ | 1784595556934352896 |
---|---|
author | Kuroda, Naoto Fujimoto, Ayataka |
author_facet | Kuroda, Naoto Fujimoto, Ayataka |
author_sort | Kuroda, Naoto |
collection | PubMed |
description | Diet therapy is an option for managing patients with drug-resistant epilepsy (DRE). Diet therapies used for patients with epilepsy include the classic ketogenic diet, the modified Atkins diet, the medium chain triglyceride diet, and the low glycemic index diet. The effectiveness of diet therapy is highly dependent on dietary adherence. Coronavirus disease (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has substantially impacted the lifestyles of people worldwide. Therefore, continuing a specific diet during the COVID-19 pandemic is expected to be difficult in some aspects. Here, based on the available literature, we summarize the perspectives for maintaining diet therapy during the COVID-19 pandemic, as a scoping review. Epileptologists and dieticians need to understand the difficulty of maintaining diet therapy during the COVID-19 pandemic. In addition, the education of patients and all stakeholders to continue diet therapy even during the current COVID-19 pandemic is crucial to control epileptic seizures. In conclusion, continuing diet therapy is not a matter only for patients during the COVID-19 pandemic, but medical staff should also help patients to overcome the problems associated with the pandemic by understanding their situations. |
format | Online Article Text |
id | pubmed-8574123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85741232021-11-08 Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review Kuroda, Naoto Fujimoto, Ayataka Epilepsy Behav Rep Article Diet therapy is an option for managing patients with drug-resistant epilepsy (DRE). Diet therapies used for patients with epilepsy include the classic ketogenic diet, the modified Atkins diet, the medium chain triglyceride diet, and the low glycemic index diet. The effectiveness of diet therapy is highly dependent on dietary adherence. Coronavirus disease (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has substantially impacted the lifestyles of people worldwide. Therefore, continuing a specific diet during the COVID-19 pandemic is expected to be difficult in some aspects. Here, based on the available literature, we summarize the perspectives for maintaining diet therapy during the COVID-19 pandemic, as a scoping review. Epileptologists and dieticians need to understand the difficulty of maintaining diet therapy during the COVID-19 pandemic. In addition, the education of patients and all stakeholders to continue diet therapy even during the current COVID-19 pandemic is crucial to control epileptic seizures. In conclusion, continuing diet therapy is not a matter only for patients during the COVID-19 pandemic, but medical staff should also help patients to overcome the problems associated with the pandemic by understanding their situations. Elsevier 2021-11-08 /pmc/articles/PMC8574123/ /pubmed/34778739 http://dx.doi.org/10.1016/j.ebr.2021.100498 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Kuroda, Naoto Fujimoto, Ayataka Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title | Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title_full | Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title_fullStr | Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title_full_unstemmed | Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title_short | Considerations for continuing diet therapy in patients with epilepsy during the COVID-19 pandemic: A scoping review |
title_sort | considerations for continuing diet therapy in patients with epilepsy during the covid-19 pandemic: a scoping review |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574123/ https://www.ncbi.nlm.nih.gov/pubmed/34778739 http://dx.doi.org/10.1016/j.ebr.2021.100498 |
work_keys_str_mv | AT kurodanaoto considerationsforcontinuingdiettherapyinpatientswithepilepsyduringthecovid19pandemicascopingreview AT fujimotoayataka considerationsforcontinuingdiettherapyinpatientswithepilepsyduringthecovid19pandemicascopingreview |